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Abstract
Background: A combined aplasia, hypoplasia or atresia of lacrimal points and salivary glands is
rarely diagnosed. Those patients suffer from epiphora, xerostomia and severe dental caries. This
phenotype represents the autosomal-dominant aplasia of lacrimal and salivary glands syndrome
(ALSG). Recently, aberrations of the Fibroblast Growth Factor 10 (FGF10) gene have been identified
to be causative for this disorder.
Methods: We performed a sequence analysis of the FGF10 gene of a patient with ALSG-syndrome
and his also affected brother as well as 193 controls. The FGF10 transcript was analyzed using RNA
extracted from primary fibroblasts of the patient's mucosa.
Results: We detected a novel heterozygous sequence variation in intron 2 (c.430-1, G > A)
causing the ALSG syndrome. The alteration derogates the regular splice acceptor site and leads to
the use of a new splice acceptor site 127 bp upstream of exon 3. The aberration was detected in
the genomic DNA derived from two affected brothers, but not in 193 control individuals.
Furthermore, no diseased member of the family displayed additional abnormalities that are
indicative for the clinically overlapping lacrimo-auriculo-dento-digital syndrome (LADD).
Conclusion: This family-based approach revealed an intronic variation of the FGF10 gene causing
ALSG-syndrome. Our results expand the mutational and clinical spectrum of the ALSG syndrome.
Background
A combined aplasia, hypoplasia or atresia of lacrimal
points and salivary glands is rarely diagnosed. Affected
patients suffer from irritable eyes, epiphora (constant tear-
ing) and xerostomia (dryness of the mouth), accompa-
nied with an increased risk of dental erosion, dental
caries, periodontal disease, and oral infections. Those
findings were described for the first time in the context of
the LADD syndrome (OMIM #149730), (also known as
Levy-Hollister syndrome) in 1967 [1]. In contrast to the
ALSG syndrome (OMIM #180920), it displays a more
severe phenotype and is characterized additionally by
anomalies of the face, teeth, digits, toes, and ears includ-
ing hearing loss, and hypospadias. Both sporadic and
familial cases have been described for both syndromes.
Recently, genes involved in the FGF signaling pathway
were associated with both syndromes. Sequence altera-
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FGFR2 and FGFR3 were described to be involved in LADD
syndrome [2,3], and aberrations of the FGF10 gene were
found to be associated with both the ALSG and the LADD
syndrome [2-6]. In the present study we describe the clin-
ical appearance of a patient that presented with an aplasia
of both lacrimal punctae and bilateral aplasia of both
parotid glands and the associated excretory ducts (ALSG
syndrome). Various members of his family were affected
suggesting a hereditary autosomal-dominant disorder.
These findings prompted us to perform genetic analysis to
identify the pathogenic sequence alteration underlying




A 34-year old, Caucasian male presented with persisting
epiphora since birth, dry mucosa of the mouth and actu-
ally a massive mucocele of the right lacrimal sac. His
brother displayed, except for the lacrimal mucoceles, the
same symptoms. Furthermore, the patient's father, grand-
mother, and grandaunt were also known to suffer from
epiphora, bad dental status and xerostomia. However,
these relatives are either deceased or were not willing to
participate in our study.
The control group comprised 193 healthy individuals
(blood donors). Patient and controls were matched with
regard to ethnicity (white Caucasians) and residence (Ger-
many).
Research was carried out in compliance with the Helsinki
Declaration. This study was presented to the ethics com-
mittee of the University of Düsseldorf and biopsies and
blood samples were obtained after informed consent.
Sequence analysis of the FGF10 gene
For sequence analysis of the FGF10 gene, blood samples
from both patient and his brother, and the control group
were obtained, and genomic DNA (gDNA) was extracted
from PBMCs using the QIAamp Blood Kit according to the
manufacturer's protocols (Qiagen, Hilden, Germany).
Quality of DNA was controlled by PCR of the beta-actin
gene. For the patient and his brother, the entire three
exons including the 5'-UTR and the 3'-UTR and flanking
intronic sequences of the FGF10 gene were amplified
applying a standard PCR protocol. PCR products were
purified, and sequence analyzed in both directions using
the BigDye v3.1 chemistry and the 310 Prism Genetic
Analysis system (Applied Biosystems, Weiterstadt, Ger-
many). Sequences obtained were screened for the pres-
ence of sequence variations by alignment analysis with
the reference sequence derived from the GenBank data-
base using the Sequence Navigator software (Applied Bio-
systems). The identified aberration was verified by
repeated sequence analysis from a new amplified PCR
product.
The frequency of the detected aberration was estimated in
the control cohort. All primer sequences, amplicon sizes,
and amplification conditions are given in Table 1.
Analysis of the FGF10 transcript
Culture of primary fibroblasts
FGF10 is known to be expressed in fibroblasts [7]. There-
fore, cell cultures of primary fibroblasts deriving from
biopsies of the mucosa from the patient and three healthy
individuals were established. Briefly, small biopsies were
obtained from oral mucosa and placed into plastic flasks
(Becton Dickinson, Heidelberg, Germany). Flasks were
flooded with fibroblast growth medium (Cambrex Bio
Science, Verviers, Belgium) and incubated under cell cul-
ture standard conditions (37°C, 5% CO2, fully humidi-
fied atmosphere). Fibroblasts grew out on day 3–5. To
transfer or passage the fibroblasts, monolayers were
washed with PBS and detached with 0.05% trypsin/0.02%
EDTA solution (Biochrom). Cells were used for analysis
between the third and the eighth passage.
Conventional RT-PCR
From each fibroblast line, total RNA was prepared on
using the RNeasy Kit including an on-column DNAse
digestion step according to the manufacturer's protocol
(Qiagen). 5 μg of total RNA was reverse transcribed using
a mixture of random 15-mer oligonucleotides and
anchored oligo-dT primers and M-MLV reverse tran-
scriptase (Sigma) in a standard protocol. Aliquots of the
conversion mixture were amplified by PCR in a thermal
cycler (Biometra, Göttingen, Germany) with specific
primers (Table 1) and Qiagen Master Mix (Qiagen), sub-
dividing the FGF10 transcript into 3 overlapping amplifi-
cation products. The resulting PCR products were
controlled using conventional agarose gel electrophoresis
and sequence analyzed according to the experimental pro-
cedure as outlined for amplificates of the genomic DNA.
The quality of the cDNA was controlled by RT-PCR of
GAPDH.
Long Range RT-PCR
To analyze for aberrantly transcripts that may include the
entire intron 2 of the FGF10 gene, we established a long
range PCR procedure using gDNA from control PBMCs as
template and primers that are located in exon 2 (sense)
and exon 3 (antisense) ensuring that both gDNA and
cDNA templates are amplified. Briefly, 200 ng gDNA were
set in a reaction volume of 50 μl using 500 μM dNTP
(each), 0.4 μM of each primer, and 4 units TripleMaster
polymerase mix in 1 × Tuning buffer (Eppendorf AG,
Hamburg, Germany) to amplify the FGF10 gene. Apply-Page 2 of 10
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Fragment Tag Sequence
Sequence analysis of the FGF 10 gene (gDNA)
5'-UTR 5-UTR-1 5'-CTC TCT CCT TGC CTT GCA TC-3'
Amplicon size: 456 bp 1–2 5'-CTG GGG GTG GAT AAT TGG A-3'
Exon 1 1-1 5'-CAA TTT CCA GTG CCG AGA GT-3'
Amplicon size: 400 bp 1–2 5'-CTG GGG GTG GAT AAT TGG A-3'
Exon 2 2-1 5'-GGA AAT ACT TGC CGG GTT TT-3'
Amplicon size: 439 bp 2-2 5'-GCC CTT GAA ACA GTG GTG AC-3'
Exon 3 3-1 5'-GGA GTT CTC TGG ATG GCT TG-3'
Amplicon size: 392 bp 3-2 5'-AAG CAG ACA TCT GCA ACG TG-3'
3'-UTR UTRS 5'-GGA GTT CTC TGG ATG GCT TG-3'
Amplicon size: 1008 bp PD3 5'-ATG CAT GTG GTG TGC TGA AT-3'
Amplification conditions:
1 × 3 min at 94°C//35 × 30 sec at 94°C, 30 sec at 60°C, 1 min at 72°C//1 × 15 min at 72°C
Sequence analysis of the FGF10 transcript (cDNA)
5'-UTR 5-UTR-1 5'-CTC TCT CCT TGC CTT GCA TC-3'
Amplicon size: 330 bp PD1 5'-TAG CTT TCT CCA GCG GAC AT-3'
Translated region
(exons 1–3) 1-1 5'-CAA TTT CCA GTG CCG AGA GT-3'
Amplicon size: 770 bp 3-2 5'-AAG CAG ACA TCT GCA ACG TG-3'
Amplification conditions:
1 × 3 min at 94°C//35 × 20 sec at 94°C, 20 sec at 60°C, 1 min at 72°C//1 × 7 min at 72°C
3'-UTR PU2 5'-TCG GAG TTG TTG CCG TCA AAG-3'
Amplicon size: 1005 bp PD3 5'-ATG CAT GTG GTG TGC TGA AT-3'
Amplification conditions:
1 × 3 min at 94°C//35 × 20 sec at 94°C, 20 sec at 63°C, 1 min at 72°C//1 × 7 min at 72°C
Analysis of alternative transcripts
Long range PCR
(Exons 2–3) PU2 5'-TCG GAG TTG TTG CCG TCA AAG-3'
Amplicon size: PD3 5'-ATG CAT GTG GTG TGC TGA AT-3'
gDNA = 6239 bp
cDNA wild type = 1005 bp
Amplification conditions:
1 × 2 min at 93°C//10 × 15 sec at 93°C, 15 sec at 65°C, 8 min at 68°C//23 × 15 sec at 93°C, 15 sec at 63°C, 8 min + 20 sec elongation per cycle at 
68°C
RT-PCR for polyacrylamid gels (semi-quantitative RT-PCR)
FGF10 Exons 1–3: E1 5'-CGG GAA GGT CAG CGG GAC CA-3'
Amplicon size: 227 bp E3as 5'-TGC TGC CAG TTA AAT GAT GC-3'
FGF10 Exons 2–3: PU2 5'-TCG GAG TTG TTG CCG TCA AAG-3'Page 3 of 10
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200 ng total RNA) were used to amplify the FGF10 tran-
script. The obtained PCR products were analyzed using
conventional agarose gels stained with ethidium bromide.
All primer sequences, amplicon sizes and amplification
conditions are given in table 1.
Identification of the aberrant transcript
The transcript in question may undergo rapid nonsense-
mediated mRNA decay and, thus, may not be detected
using conventional agarose gels stained with ethidium
bromide. Therefore, we decided to use a more sensitive
separation and detection system. RT-PCR amplificates
were separated on precasted polyacrylamid gels (Clean-
Gel, Amersham Biosciences, Freiburg, Germany) accord-
ing to the manufacturers' protocol and silver stained
(DNA Silver Staining Kit, Amersham Biosciences). Aber-
rant bands were excised from the polyacrylamid. The
excised fragments were placed in dH2O and heated for 30
min at 95°C. 1 μl of the eluted DNA was re-amplified and
the resulting PCR product was sequenced.
Algorithmic splice site prediction
To analyze the effect of the intronic alteration on mRNA
splicing, we conducted automated splice site prediction
using two software programs (NetGene2 and NNSplice




GenBank: human FGF10 transcript, NM_004465.1;
human FGF10 gene, AY604046.1
Results
Clinical features
We examined a patient and his brother with clinical find-
ings of the hereditary ALSG-syndrome.
Amplicon size: 416 bp E3, 3'-UTR 5'-CCT TCA AAG GCT GGC TTT CT-3'
beta-2-microglobulin B2Ms 5'-TTC ATC CAT CCG ACA TTG AA-3'
Amplicon size: 465 bp B2Mas 5'-TCT CTG CTC CCC ACC TCT AA-3'
Amplification conditions:
1 × 15 min at 95°C//40 × 30 sec at 93°C, 90 sec at 60°C, 1 min at 72°C//15 min at 72°C
(aberrant transcript detection)
1 × 15 min at 95°C//32 × 30 sec at 93°C, 90 sec at 60°C, 1 min at 72°C//15 min at 72°C
Analysis of the FGF10 transcript stability (cDNA, real time RT-PCR)
Exon 1/2 P1 5'-CTC CTT CTC CTC TCC TT-3'
Amplicon size: 179 bp P2 5'-GAT GTT ATC TCC AGG ATG CTG TA-3'
Probe E1/2 5'-GCT ATT CTC TTT CAC C-3'
Exon 2/3 P3 5'-GGG AAA CTC TAT GGC TCA AAA-3'
Amplicon size: 110 bp P4 5'-CCT CCC ATT ATG CTG CCA GTT A-3'
Probe E2/3 5'-GGA AAA TGG ATA CAA TAC-3'
Amplification conditions:
1 × 15 min at 95°C//35 × 15 sec at 94°C, 30 sec at 56°C, 30 sec at 76°C
Control amplifications
GAPDH (cDNA) GA1 5'-ACC ACA GTC CAT GCC ATC AC-3'
Amplicon size: 451 bp GA2 5'-TCC ACC ACC CTG TTG CTG TA-3'
Amplification conditions:
1 × 3 min at 94°C//25 × 20 sec at 94°C, 20 sec at 66°C, 30 sec at 72°C//1 × 7 min at 72°C
beta-actin (gDNA) BA1 5'-AGG CCA ACC GCG AGA AGA TGA-3'
Amplicon size: 732 bp BA2 5'-GAA GTC CAG GGC GAC GTA GCA-3'
Amplification conditions:
1 × 3 min at 94°C//30 × 20 sec at 94°C, 20 sec at 60°C, 30 sec at 72°C//1 × 7 min at 72°C
Table 1: Oligonucleotide primers for amplification and sequence analysis of FGF10 in transcript and genomic DNA, and quality 
controls. (Continued)Page 4 of 10
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punctae associated with a mucocele of the lacrimal sac
imposing as a benign soft tumor in the region of the
medial right canthus and bilateral aplasia of both parotid
glands and the excretory ducts (Fig. 1a). In addition, pros-
thetical and conservatively treated teeth after caries-
related destruction, especially in the region of the molars,
were observed (Fig. 1b). The mucocele which had already
led to bony erosion of the os lacrimale was seen in ultra-
sonography as well as in the computer tomography scan
(Fig. 1c–d). Those images confirmed a total aplasia of
both parotid glands also, whereas both submandibular
and sublingual glands were present (Fig. 1e). An endo-
scopic dacryocystorhinostomia interna (West operation)
was performed on both sides to drain the lacrimal sacs.
Clinical examination of the patient's brother who, except
for the lacrimal mucocele, suffered from the same symp-
toms, also revealed an aplasia of both lacrimal punctae
and a total aplasia of submandibular, sublingual as well as
parotid glands. In addition, his teeth were treated in a
prosthetical and conservative way. Anomalies of the teeth,
fingers, toes, and ears including hearing loss were neither
found in the patient nor in his brother. The genitourinary
system was normal.
Mutation analysis
The recently described interrelation between the ALSG
syndrome and alterations in the FGF10 gene prompted us
to perform sequence analysis of the entire three exons, the
5'- and 3'-UTRs, and exon flanking sequences of the
FGF10 gene in gDNA derived from patient's PBMCs. Five
different single nucleotide polymorphisms are described
for the FGF10 transcript with variable allele frequencies,
located in the 5'-UTR, in the translated part of exon 3 and
in the 3'-UTR (1, 1, and 3 polymorphisms, respectively).
However, none of these SNPs was found. However, we
Computer tomography scans demonstrating the pathological findings of an ALSG patientFigure 1
Computer tomography scans demonstrating the pathological findings of an ALSG patient. The pathological areas 
are marked. 1a: The patient shows an aplasia of both lacrimal punctae associated with a mucocele of the lacrimal sac imposing 
as a benign soft tissue tumor in the region of the medial canthus. 1b: Prosthetically (gold cap) treated teeth after caries-related 
destruction, especially in the molar region. 1c-d: Axial (c) and coronal (d) computer tomography scan demonstrating mucoce-
les originating from the lacrimal sac. The os lacrimale is partly destroyed, on the right side more pronounced than on the left 
side. 1e: Axial computer tomography scan showing a total aplasia of both parotid glands.Page 5 of 10
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nal nucleotide of intron 2 (c.430-1, G > A) altering the
consensus motif for splice site recognition (Fig. 2). The
aberration was also found in gDNA isolated from PBMCs
of the patient's brother who also suffers from ALSG. More-
over, it was not detected in gDNA derived from 386 con-
trol chromosomes nor reported in the GeneSnp database
or in the Human Gene Mutation database available at
http://www.genome.utah.edu/genesnps/ and http://
www.hgmd.cf.ac.uk/ac/index.php, respectively.
Effects on mRNA splicing
To assess whether the alteration affects mRNA splicing of
FGF10, two different splice site prediction algorithms
were used. Both algorithms identified the donor and
acceptor sites of the three exons of the FGF10 gene cor-
rectly when provided with the wild type sequence. In con-
trast, after substitution of the terminal nucleotide of
intron 2 the loss of the splice acceptor site of exon 3 was
anticipated by both of the algorithms. Moreover, both
algorithms show potential alternative splice sites in intron
2 or exon 3 which would result in the addition of parts of
intron 2 or the deletion of exon 3 sequences (Table 2).
In order to determine the actual effect of the c.430-1, G >
A aberration on FGF10 mRNA splicing, we undertook sev-
eral experimental approaches. FGF10 is known to be
expressed in fibroblasts. Therefore, we established pri-
mary fibroblast cells from both the patient and three
healthy individuals and analyzed the FGF10 transcript.
To eliminate the possibility of the inclusion of the entire
intron 2, which is too large to be amplified under normal
PCR conditions, a long range RT-PCR protocol was estab-
a: A heterozygous sequence variation in the terminal nucleotide of intron 2 of the FGF10 gene (g.85478 corresponding to c.430-1, G > A) was detect d which alters th  consens s motif f r splice acceptor site recognitionFigur  2
a: A heterozygous sequence variation in the terminal nucleotide of intron 2 of the FGF10 gene (g.85478 corre-
sponding to c.430-1, G > A) was detected which alters the consensus motif for splice acceptor site recognition. 
The upper panel shows a representative electropherogram of a healthy individual. The middle and the lower panel demon-
strate the sequence variation in genomic DNA derived from the patient and his brother. The changed nucleotide is marked by 
an arrow. 2b: Chart showing the exon/intron structure of the FGF10 gene. The characteristic polypyrimidine stretch and the 
consensus acceptor site are shown. The changed nucleotide is marked by an arrow.Page 6 of 10
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Table 2: Splice site prediction with NNSplice 0.9 and NetGene2 v. 2.4. Both algorithms anticipate the loss of the regular splice 
acceptor site of FGF10 exon 3 caused by the c.430-1, G > A aberration. Several alternative acceptor splice sites are proposed. 
Localization according to GenBank Accession No. AY604046.1.
NNSplice 0.9
Acceptor site predictions:
Start End Sequence (5'-> 3') Function
80131 80150 tatgttttaggcatcctgga Exon 2 acceptor
85469 85488 tcctttgcagaaagaattta Exon 2 acceptor
Alternative acceptor sites:
Start End Sequence (5'-> 3') Localization Effect on FGF10 transcript
81353 81372 tccctcccagagacagatca Intron 2 insertion of 4116 bp
81899 81918 ctaatatcaggtccactttt Intron 2 insertion of 3570 bp
82609 82628 ctcccaatagattgtgacct Intron 2 insertion of 2860 bp
84430 84449 ctatttttagtatagacggg Intron 2 insertion of 1039 bp
85062 85081 tttccttcagttctattttt Intron 2 insertion of 407 bp
86294 86313 tctttctaagttatttattt Exon 3, 3'-UTR deletion of 825 bp
86384 86403 ttttattcagcacaccacat Exon 3, 3'-UTR deletion of 915 bp
NetGene2 v. 2.4
Acceptor site predictions:
position 5'-> 3' Sequence (5'-> 3') Function
80140 TATGTTTTAG*GCATCCTGGA Exon 2 acceptor
85478 TCCTTTGCAG*AAAGAATTTA Exon 2 acceptor
Alternative acceptor sites:
position 5'-> 3' Sequence (5'-> 3') Localization Effect on FGF10 transcript
82618 CTCCCAATAG*ATTGTGACCT Intron 2 insertion of 2860 bp
86393 TTTTATTCAG*CACACCACAT Exon 3, 3'-UTR deletion of 915 bp
BMC Medical Genetics 2008, 9:114 http://www.biomedcentral.com/1471-2350/9/114lished that works to amplify the 6.2 kb-fragment spanning
from exon 2 to exon 3 using gDNA as template. However,
applying the same protocol on the patient's cDNA no
accordant PCR product was present (Fig. 3).
In case that one of the potential acceptor sites is used, RT-
PCR amplificates of the affected and the wild type tran-
script deviate in molecular size. However, FGF10 mRNA
amplificates from the patient did not show an anomalous
molecular weight by size separation using conventional
agarose gel electrophoresis. In contrast, using the more
sensitive separation and detection system of silver-stained
polyacrylamid gels, we were able to identify aberrant
migrating fragments in RT-PCR reactions using two differ-
ent primer combinations for the patient's samples but not
for control samples (Fig. 4a). Re-amplification and
sequence analysis of the excised DNA fragments revealed
the use of an alternative acceptor splice site upstream of
exon 3 that results in the insertion of additional 127 bp
into the FGF10 transcript (Fig. 4b). However, this acceptor
splice site has not been foretold by any of the splice site
prediction algorithms. The insertion leads to a prelimi-
nary translation stop codon after the insertion of three
novel amino acids following amino acid 143 (Fig. 4c).
Discussion
Recently, Entesarian et al. [5] showed that alterations of
the FGF10 gene are causative for the described phenotype.
In each of two diseased families a heterozygous sequence
variation of the FGF10 gene was detected and an auto-
somal-dominant hereditary transmission was docu-
mented. The alteration of one family represents a 53-kb
deletion concerning exons 2 and 3, and the other family
carried a nonsense mutation (p.R193X; c.577C > T).
Because both alterations result in the loss of major parts
of the FGF10 protein they are considered to be non-func-
tional. A correlation of these FGF10 aberrations and spo-
radic cases of sicca-syndrome with symptoms identical to
those of individuals with ALSG was excluded by screening
DNA samples from 74 patients. Moreover, heterozygous
FGF10 mice developed the same phenotype [5]. More
recently, two missense mutations of the FGF10 gene
(p.R80S; c.240A > C and p.G138E; c.413G > A) were
shown to be causative for the ALSG syndrome [4]. Both of
these mutations exchange highly conserved and function-
ally important residues suggesting the production of a
non-functional protein or a protein with an altered func-
tion. In addition, the LADD syndrome is also caused by
FGF10 mutations indicating that both syndromes are
allelic disorders and part of the same phenotypic spec-
trum [2,6]. Here, two missense mutations in exon 1
(p.C106F; c.317G > T) and exon 3 (p.I156R; c.467T > G),
and a nonsense mutation in exon 2 (p.K137X; c.409A > T)
were detected.
These studies prompted us to perform genetic analysis to
identify the pathogenic sequence alteration underlying
the mild phenotype of the ALSG syndrome in the German
family.
We detected a novel FGF10 sequence variation in intron 2
altering the consensus acceptor site of the terminal exon 3
(c.430-1 G > A). This may affect the resulting transcript in
different ways. Due to the use of an alternative acceptor
site in either intron 2 or exon 3, additional flanking
intronic sequences may be inserted, or the 5'-part of exon
3 may be deleted, frequently resulting in a frameshift. In
fact, we were able to find an altered transcript in patient's
mucosal fibroblast cells. The FGF10 alteration causes the
use of an alternative acceptor splice site which is located
127 bp upstream of exon 3. This mutation results in a pre-
mature translation termination codon immediately after
the insertion of three novel amino acids following exon 2.
As a consequence the peptide lacks a large C-terminal part
of the molecule and will probably not have any biological
activity because its FGF10 core will have been severely dis-
rupted.
Transcripts containing frameshift or nonsense mutations
that cause premature translation termination codons are
often degraded by the nonsense-mediated mRNA decay
mechanism [8]. It is known, that aberrations in the 5'-UTR
or 3'-UTR may result in instability of mRNA. However,
Analysis of FGF10 transcript applying long range RT-PCRFigure 3
Analysis of FGF10 transcript applying long range RT-
PCR. In order to analyze for transcripts that may include the 
entire intron 2, a long range RT-PCR protocol was estab-
lished that works to amplify the 6.2 kb-fragment spanning 
from exon 2 to exon 3 using gDNA as template. Applying the 
optimized conditions to amplify the FGF10 transcript, no 
accordant PCR product was present. 1, 3: patient; 2, 4: con-
trol; MW: molecular weight marker.Page 8 of 10
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Detection and analysis of an aberrant transcriptFigure 4
Detection and analysis of an aberrant transcript. 4a: Separation of FGF10 RT-PCR amplificates using sensitive silver-
stained polyacrylamid gels reveals additional fragments for the patient's samples but not for control samples. Upper panel, 
Amplification of the FGF10 transcript using oligonucleotides designed to amplify exon 1 to exon 3 sequences; Lower panel, 
Amplification of the FGF10 transcript using oligonucleotides designed to amplify exon 2 to exon 3 sequences. C: control; P: 
patient. 4b: Sequence analysis of the excised and re-amplified additional exon 1/exon 3 fragment. The c.430-1, G > A aberration 
results in the use of an alternative splice acceptor site 127 bp upstream of exon 3. 4c: Putative effect of the 127 bp insertion on 
protein translation.
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sequence analysis did not identify any further alteration.
On the other hand, additional nucleotide variation in the
promoter of the FGF10 gene could lead to diminished
transcription for example through abrogation of tran-
scription factor binding sites.
The LADD- and ALSG syndromes are allelic disorders.
However, the majority of the detected FGF10 mutations
are described to cause the milder ALSG syndrome –
including ours – are predicted to result in a non-func-
tional protein. Recent studies and our findings suggest
that changed FGF10 signaling due to haploinsufficiency
during development results in ALSG. In contrast, for
LADD syndrome patients two FGF10 missense alterations
were found which result in the exchange of less conserved
residues suggesting residual or possibly altered activity of
the aberrant protein [4].
Conclusion
To the best of our knowledge, this is the first report of a
splicing mutation in the FGF10 gene. The detected muta-
tion leads to the insertion of additional intronic 127 bp
upstream of the terminal exon 3. This alteration does not
add up in more severe anomalies which are associated
with the allelic LADD syndrome but in a mild ALSG phe-
notype. To date, no functional differences are described
between FGF10 ALSG and LADD mutations. Future clini-
cal and genetic investigations of additional affected fami-
lies are mandatory to provide the rationale to distinguish
the clinical outcome of the disruption of FGF10 signaling.
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